Empowering women to live healthier lives!
Text size
Email
Print
Omontys Approved for Anemic People With Kidney Disease
TUESDAY, March 27 (HealthDay News) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.
Anemia is characterized by a lack of enough healthy red blood cells. The newly approved drug is designed to stimulate bone marrow to produce more of these cells, reducing a person's need for a blood transfusion, the FDA said Tuesday in a news release.
Clinical testing of the once-monthly injection involved 1,608 people with abnormally low hemoglobin, a measure of anemia. The most common side effects were diarrhea, vomiting, high blood pressure and pain in the joints, back, legs or arms, the agency said.
Omontys should not be used in people with chronic kidney disease who are not on dialysis, nor those with cancer-related anemia, the FDA warned. It should also not be used as a substitute in people who require an immediate blood transfusion to treat anemia.
Omontys is marketed by Palo Alto, Calif.-based Affymax Inc.
More information
The U.S. National Library of Medicine has more about anemia.
Copyright © 2012 HealthDay. All rights reserved.
HealthDay news articles are derived from various sources and do not reflect federal policy. Womenshealth.gov does not endorse opinions, products, or services that may appear in news stories.
A federal government website managed by the Office on Women's Health in the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services.200 Independence Avenue, S.W. • Washington, DC 20201
202-690-7650 • Monday through Friday, 9 a.m. to 5 p.m. EST (closed on federal holidays).
womenshealth.gov
A federal government website managed by the Office on Women's Health in the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services.
200 Independence Avenue, S.W. • Washington, DC 20201